Search - tctmd.com

Displaying 1 - 13 of 13

Sort: Relevancy | Date

News Daily News

FDA Drops REMS Requirement for Antihypertensive Aprocitentan

Michael O'Riordan

April 09, 2025

News Daily News

Biden White House Delays Decision on Menthol Ban

Michael O'Riordan

December 07, 2023

News Daily News

‘Overwhelming Reduction’ in Bleeding With Abelacimab vs Rivaroxaban in AF

L.A. McKeown

September 18, 2023

News Daily News

DELIVER Trial Scores a Win for Dapagliflozin in HFpEF

L.A. McKeown

May 05, 2022

News Daily News

FDA Investigating Possible Sex Differences in LAAO Outcomes

Todd Neale

September 27, 2021

News Daily News

Cardiology Societies Unite to Condemn Racism and Health Inequality

L.A. McKeown

June 01, 2020

News Daily News

CV Safety Trial for Lorcaserin Picks Up Cancer Signal: FDA

Shelley Wood

January 14, 2020

News Daily News

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Michael O'Riordan

November 14, 2019

News Daily News

FDA Tallies Cases of Fournier Gangrene in Patients Taking SGLT2 Inhibitors

Michael O'Riordan

May 08, 2019

News Daily News

TCTMD’s Top 10 Most Popular Stories for April 2019

Shelley Wood

May 01, 2019

News Daily News

Recall: Clopidogrel Tablets Mislabeled, May Contain Statin

L.A. McKeown

January 11, 2018

News Daily News

USPSTF: Not Enough Evidence to Recommend Routine Lipid Screening in Children and Adolescents

Michael O'Riordan

August 09, 2016

News Daily News

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Michael O'Riordan

June 30, 2016

Advertisement

FDA Drops REMS Requirement for Antihypertensive Aprocitentan

Biden White House Delays Decision on Menthol Ban

‘Overwhelming Reduction’ in Bleeding With Abelacimab vs Rivaroxaban in AF

DELIVER Trial Scores a Win for Dapagliflozin in HFpEF

FDA Investigating Possible Sex Differences in LAAO Outcomes

Cardiology Societies Unite to Condemn Racism and Health Inequality

CV Safety Trial for Lorcaserin Picks Up Cancer Signal: FDA

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

FDA Tallies Cases of Fournier Gangrene in Patients Taking SGLT2 Inhibitors

TCTMD’s Top 10 Most Popular Stories for April 2019

Recall: Clopidogrel Tablets Mislabeled, May Contain Statin

USPSTF: Not Enough Evidence to Recommend Routine Lipid Screening in Children and Adolescents

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content